Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 7/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6448936 | 0.90 | KMT2A (0.51) | MAPTRXFP1PTGER3LMNARAB9A | |
| SCHEMBL6447202 | 0.89 | KMT2A (0.46) | MAPTPTGER3RAB9AKDM4EPOLB | |
| SCHEMBL6444242 | 0.89 | RAB9A (0.52) | MAPTRXFP1PTGER3LMNARAB9A | |
| SCHEMBL6445978 | 0.88 | SNCA (0.47) | RXFP1PTGER3LMNARAB9AKDM4E | |
| SCHEMBL6447053 | 0.87 | CSNK2A2 (0.49) | MAPTRXFP1CTSDPTGER3RAB9A | |
| SCHEMBL6445760 | 0.87 | CSNK2A2 (0.52) | MAPTRXFP1PTGER3RAB9AKDM4E | |
| SCHEMBL6445872 | 0.86 | NPC1 (0.53) | MAPTRXFP1RAB9AKDM4E | |
| SCHEMBL6445816 | 0.86 | BCAT2 (0.49) | MAPTRXFP1PTGER3LMNARAB9A | |
| SCHEMBL6446020 | 0.86 | KMT2A (0.48) | MAPTRXFP1PTGER3LMNARAB9A | |
| SCHEMBL6444705 | 0.85 | MAPK1 (0.57) | MAPTLMNARAB9AKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143384-A1 | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-30 | — | — | US | claimed |
| US-20050143384-A1 | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143384-A1 | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 | SERPINE1, SERPINC1, SERPINB1 | MAPT 3346/4885RXFP1 508/4885CTSD 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.